Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform generated approximately 10 ng/mL of EpCAM-targeted TCE directly within tumors following IV delivery, without systemic administration of the TCE protein itself, turning the tumor into a localized TCE biofactory SAN DIEGO , Oct. 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced that it presented two posters at the European Society for Medical Oncology (ESMO) Congress 2026 last week in Madrid . The presentations showcased new data from the Company’s RedTail platform, a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors. Together, the presentations demonstrated the RedTail platform's expanding flexibility, from CLD-401-mediated tumor immune priming to dual-payload candidates designed for localized T-cell redirection. The Company continues to expand the functionality of the RedTail platform and is pursuing strategic partnerships to accelerate clinical development and broaden its impact. On October 24, 2026 , the Company presented preclinical data on its lead program, CLD-401, showing complete tumor eradication in 80% of EMT6 breast cancer tumor-bearing mice versus 0% in the control arm. CLD-401 was engineered for systemic delivery, and new data from an MB49 bladder cancer model show it retains antitumor activity with either systemic intravenous or localized intratumoral administration, supporting flexible delivery approaches across tumor accessibility and disease settings. A link to the poster can be found here . CLD-401 is a systemically delivered virotherapy designed to selectively target tumors and enable high-level expression of IL-15 superagonist (“IL-15 SA”), a known T- and NK-cell activator, driving profound immune changes in the tumor microenvironment (“TME”), including the recruitment and activation of NK, NK-T, and gamma delta (γδ) T-cells that lead to a robust therapeutic response in immunocompetent animal models. Also on October 24, 2026 , the Company presented preclinical data on CLD-501, the lead compound from its in situ T-cell engager (“TCE”) platform, including its TROP-2-targeted candidate, and CLD-502, its EpCAM-targeted candidate. Data from the EpCAM-targeted construct also showed that incorporation of an additional TCE payload did not reduce expression of the co-encoded IL-15 SA payload in the reported in vitro or in vivo studies. Both candidates are systemically delivered RedTail virotherapies designed to selectively target tumors and enable localized co-expression of a tumor-targeted TCE and IL-15 SA . The presentation showed antigen-dependent, dose-responsive T cell-mediated cytotoxicity for TROP-2- and EpCAM-targeted TCEs. By converting tumors into localized biofactories expressing TCEs and T cell-activating payloads, generating approximately 10 ng/mL of EpCAM-targeted TCE directly within tumors following IV delivery, the In Situ TCE platform addresses the toxicity, tumor-exposure, and immunosuppressive TME barriers associated with systemically administered TCEs in solid tumors. A link to the poster can be found here . About Calidi Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, is being developed for metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform with its novel In Situ T-cell engager approach for solid tumors, including CLD-501, its TROP-2-targeted candidate, and CLD-502, its EpCAM-targeted candidate. Calidi Biotherapeutics is headquartered in San Diego, California . For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here . Forward-Looking Statements This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “c